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Summary 
Natural killer cell stimulatory factor (NKSF) is a 70-kD heterodimeric cytokine that was initially 
isolated from conditioned medium of human B lymphoblastoid cell lines. The effects of recombinant 
NKSF  on the function of human peripheral blood NK cells were examined.  NKSF  directly 
augmented the cytolytic activity of freshly isolated NK cells. Both CD56 dim and CD56b~ ht NK 
ceils demonstrated enhanced cytotoxicity after brief exposure to NKSF. In contrast, highly purified 
T lymphocytes did not exhibit major histocompatibility complex-unrestricted cytotoxicity after 
short-term culture with NKSF.  Like interleukin 2 (I1-2),  NKSF augmented the lysis of NK- 
sensitive,  NK-resistant,  and  antibody-coated  targets.  Both  NKSF  and  IL-2  induced  marked 
upregulation of several NK cell adhesion molecules known to participate in cytolysis, including 
CD2, CDlla,  and CD54. However, NKSF activates NK cells through a pathway distinct from 
that of I1-2, since the presence of anti-I1-2 receptor (anti-I1-2R) antibodies or I1-4 did not inhibit 
the effects of NKSF.  NKSF by itsdf induced very little proliferation of resting NK cells.  NK 
cells preactivated in vitro with II-2 demonstrated enhanced proliferation to NKSF, but the degree 
of proliferation was always inferior to that induced by I1-2 alone. Moreover, NKSF  strongly 
inhibited I1-2-induced proliferation of either resting or preactivated NK cells.  This inhibition 
was not the result of decreased I1-2R expression, because NKSF-activated NK cells expressed 
higher levels of both I1-2Rs p75 and p55. Furthermore, NKSF did not inhibit the proliferation 
of mitogen-activated T  cells, indicating a selective effect on NK cell proliferation. Human NK 
cells expanded in vivo by prolonged continuous infusions of II.-2 remained fully responsive to 
NKSF. Picomolar concentrations of NKSF were as effective as nanomolar concentrations of I1-2 
in augmenting the cytolytic activity of NK cells expanded in vivo by 11-2. NKSF may play an 
important role in the regulation of human NK cell function, and its possible use as a therapeutic 
cytokine deserves further investigation. 
N 
'K  cells are lymphocytes that  can lyse certain tumor 
cells and virus-infected cells spontaneously and without 
MHC restriction (1, 2). Unlil~e T  and B cells, NK cells do 
not productively rearrange either TCK or Ig genes (1, 3, 4) 
and  do not  appear  to  possess donotypic,  antigen-specific 
receptors (1,  2,  4).  Although the receptors responsible for 
triggering NK cytolysis remain poorly characterized, the cyto- 
lytic activity of these lymphocytes can be regulated by sev- 
eral cytokines (1,  2).  Sufficient concentrations of Ib2 dra- 
matically  enhance  NK  cytotoxicity  and  induce  NK  cell 
proliferation (5-7), and I1-2-activated NK cells appear to be 
largely responsible for the LAK phenomenon (8-10). Adminis- 
tration of high doses of I1-2, with or without adoptive transfer 
of LAK cells generated in vitro, can induce tumor regres- 
sions in experimental animals and patients with  advanced 
cancer (11-14).  However, high-dose I1-2 therapy is associated 
with substantial toxicity (15), and only a small minority of 
patients demonstrates objective response to such therapy (13, 
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ifications in the dose and schedule of I1.-2 or the use of addi- 
tional cytokines (14). 
Natural killer cell stimulatory factor (NKSF) 1 is a 70-kD 
disulfide-linked heterodimeric glycoprotein composed of 35- 
and 40-kD subunits (16, 17). NKSF was initially purified from 
the medium of human B  lymphoblastoid cell lines stimu- 
lated with phorbol ester (16).  NKSF has several biologic ac- 
tivities in vitro, including the induction of IFN-3, secretion 
by T cells and NK cells, augmentation of MHC-unrestricted 
cytolytic activity of unfractionated PBMC, and enhancement 
of proliferation of mitogen-activated PBMC  (16-18).  The 
cDNA encoding NKSF is virtually identical to that of cyto- 
toxic lymphocyte maturation factor or II,12  (19-21).  The 
effects of NKSF, or II.-12, on highly purified human periph- 
eral blood NK cells have not been reported in detail. We de- 
scribe the disparate effects of NKSF on NK cell cytolytic ac- 
tivity and proliferation, and the differential regulation of NK 
cell and T cell proliferation by NKSF. The possible implica- 
tions of these results for anticancer immunotherapy are dis- 
cussed. 
Materials  and Methods 
Antibodies.  Fluorochrome-conjugated murine mAbs were ob- 
tained from Coulter Immunology (Hialeah,  FL), including T3 
(CD3), Tll (CD2), Mol (CD11b), NKH1 (CD56), IL-2R1 (CD25), 
and isotype-matched control mAb. FITC-conjugated Leu-1 (CD5) 
was purchased  from Becton Dickinson & Co. (Mountain View, 
CA). FITC-conjugated anti-ICAM-1 (CD54) was purchased from 
AMAC,  Inc.  (Westbrook,  ME).  T1  /24T6G12  (CD5),  2F12 
(CDlla), MY4/322A (CD14), B1/H299 (CD20), and IL-2R p55 
/1HT44H3  (CD25)  were produced as ascites in BALB/c mice 
bearing hybridoma tumors. Murine mAb 2K-B, directed against 
the p75 subunit of the human Ib2R (22), was provided by Coulter 
Immunology. 
Cell Lines.  K562  (a myeloid cell line derived from a patient 
with chronic myelogenous leukemia in blast crisis), COLO 205 
(a colon adenocarcinoma  cell line), and P815 (a murine mastocy- 
toma cell line) were all obtained from the American Type Culture 
Collection (Rockville,  MD).  Cell lines were maintained in con- 
tinuous suspension cultures in RPMI 1640 (Gibeo Laboratories, 
Grand Island, NY) supplemented  with 10% FCS, 2 mM L-gluta- 
mine,  1 mM sodium pyruvate,  penicillin,  and streptomycin. 
Preparation of Recombinant Human NKSF and Anti-NKSF I-Ieter- 
oantiserum.  Cos-1  cells or CHO ceils were transfected with cDNAs 
encoding both the NKSF p35 and 1040 chains by a method previ- 
ously described (23). Conditioned medium of transfected Cos ceils 
was used as the source ofrNKSF in most experiments. This prepa- 
ration contained 2,500 U/ml of NKSF activity, as determined in 
a PHA blast proliferation  assay. 1 U/ml NKSF is approximately 
equivalent  to 3.5  pM (16). For some experiments,  rNKSF was 
purified from the supematants of transfected CHO cells by a method 
similar to that previously described for the purification of natural 
NKSF (16). A neutralizing rabbit antiserum to NKSF was pre- 
pared as previously described (18). 
1 Abbreviations used in this patx,  r: ADCC, antibody-dependent  cell-mediated 
cytotoxicity; CAM, cell adhesion molecule; NKSF, natural killer cell 
stimulator,/factor. 
Commercial Cytokines and Reagents.  All commercial cytokines 
were recombinant human proteins.  Ib2 (sp act, 1.5  x  107 U/mg 
protein) and IFN-oe were provided by Hoffmann-La Roche,  Inc. 
(Nutley, NJ);  1 U/m1 of IL-2 is approximately equivalent  to 4.4 
pM. I1.,4 was provided by Schering-Plough Corp. (Bloomfield, NJ) 
and IFN-~/  (2.5  x  107 U/mg)  was  purchased  from Genzyme 
(Cambridge, MA). PHA was purchased from Burroughs WeUcome 
Co. (GreenviUe, NC), PMA from Sigma Chemical Co. (St. Louis, 
MO), and ionomycin from Calbiochem-Behring Corp. (La Jolla, 
CA). 
Isolation and Culture of Lymphocytes.  PBMC were isolated on 
a Ficoll-diatrizoate gradient from beparinized venous blood or from 
cytopheresis buffy coats obtained from normal volunteer donors. 
Adherent mononudear ceils were depleted by incubation on plastic 
petri dishes for 1 h at 37~  Enriched NK cells were obtained by 
incubating PBL with a mixture of excess T1/24T6G12, B1/H299, 
and MY4/322A mAbs, and then separating antibody-bound cells 
using immunomagnetic beads (Advanced Magnetics,  Cambridge, 
MA). The resulting T  ceil, B cell, and monocyte-depleted  PBL 
consisted of 65  _+  14% CD56 + ceils (mean  +_ SD of nine experi- 
ments) and 11  _+  7%  CD3 + cells; only 2  _+  1% of these cells 
coexpressed CD56 and CD3. Highly purified CD5-CD56 + NK 
cells and CDS+CD56 -  T cells were isolated from PBL by stan- 
dard methods (24) using an EPICS 752 flow cytometer (Coulter 
Electronics, Hialeah, FL). CD56  aim and CD56  b~sht NK cell subsets 
were obtained by flow cytometry as described previously (25). The 
CD56 mAb used does not affect NK cell proliferation or cytolytic 
activity (26-28).  Lymphocytes were incubated in either 25-cm 2 
tissue culture flasks (Becton Dickinson Labware, Lincoln Park, NJ) 
or  96-well  U-bottomed  microtiter  plates  (Flow  Laboratories, 
McLean, VA) at a concentration of 1-2  x  106/ml in 5% CO2 hu- 
midified  air  at  37~  Culture  medium was  RPMI  1640 sup- 
plemented with 15% heat-inactivated,  pooled human AB serum, 
2 mM t-glutamine,  1 mM sodium pyruvate, penicillin, streptomycin, 
and gentamycin. Recombinant cytokines were added to some cul- 
tures at the concentrations indicated. 
ImmunofluorescenceStudies.  Samples  of cells were stained directly 
or indirectly with fluorochrome-conjugated mAb, washed,  fixed 
in 1% formaldehyde, and analyzed by flow cytometry as previously 
described (28). Because cultured lymphocytes often demonstrated 
high background fluorescence, such ceils were centrifuged through 
a Ficoll gradient to remove dead cells and debris before staining. 
Cytotoxicity Assays.  For NK activity assays, target ceils were 
incubated for 1 h at 37~  with 150/xCi of NaSlCrO4, washed 
twice,  and  plated  at  3,000  or  5,000  ceils per  well in  96-well 
U-bottomed microtiter plates. Effector cells were then added to 
triplicate wells to yield various E/T ratios in a final volume of 200 
/zl. After a 4-h incubation at 37~  the microtiter plates were cen- 
trifuged and well supernatants were collected using a cell harvester 
(Skatron, Inc., Sterling, VA). Supematant radioactivity was assayed 
using an automated gamma counter (LKB Wallac, Turku, Finland). 
For antibody-dependent cell-mediated cytotoxicity  (ADCC) assays, 
P815 cells were preincubated  with medium or with a 1:100 dilu- 
tion of polyclonal rabbit anti-mouse lymphocyte serum (Accurate 
Chemical & Scientific Corp., Westbury, NY) and then labeled with 
slCr for 1 h at 37~  Chromium release was determined as de- 
scribed for NK activity assays. For all cytotoxicity  assays, maximum 
chromium release was determined by addition of 1% NP-40 deter- 
gent and minimum release by addition of medium alone to target 
cells. Spontaneous release was generally <10% and never exceeded 
20% of maximum release for the experiments  reported.  Specific 
cytotoxicity was calculated using a standard  formula (29). 
Proliferation Assays.  Sorted lymphocyte subsets were plated at 
780  Response  of Human NK Cells to NK Cell Stimulatory Factor 30,000 cells per well in 96-well U-bottomed microtiter  plates in 
medium alone or medium containing various stimuli as indicated. 
Unless otherwise noted, 1/LCi of [3H]TdR was added to each well 
after 4 d of culture.  Samples were collected 18 h later  using  a 
cell harvester  (Cambridge  Technology,  Watertown,  MA),  and 
[3H]TdR incorporation  was measured using a liquid scintillation 
counter (Packard Instrument,  Downers Grove, IL). For preactiva- 
tion experiments, the fold increase in counts per minute associated 
with preactivation was calculated as follows: (cpm of preactivated 
cells cultured  in NKSF  -  cpm of preactivated cells cultured  in 
medium)/(cpm of resting cells cultured in NKSF -  cpm of resting 
cells cultured in medium). NK cells were preactivated for 18 h with 
10 ng/ml PMA, 1/~M ionomycin, or 1,000 U/ml II~2, and T cells 
were preactivated with 5/zg/ml PHA as indicated. 
Results 
Effects of NKSF on the Cytolytic Activity of Human NK 
Cells.  rNKSF augmented the cytolytic activity of enriched 
peripheral blood NK cells in a dose-dependent manner.  Al- 
though enhanced cytolytic activity was evident after stimu- 
lation of NK cells with as little as 0.1 U/ml of NKSF, op- 
timal enhancement required  NKSF concentrations in the range 
of 1-10 U/ml ('~3.5-35 pM; data not shown). These results 
are in close agreement with those obtained previously using 
purified natural NKSF and unfractionated PBL (16). Incuba- 
tion with comparable dilutions of supernatants from mock- 
transfected Cos ceils did not augment the cytotoxicity of NK 
cells,  and the NKSF-induced enhancement  of NK cytolysis 
could be completely abrogated by a neutralizing  heteroan- 
tiserum to NKSF (data not shown).  The augmentation  of 
NK cytotoxicity is thus a specific effect of rNKSF and not 
due to contaminating  factors in the Cos cell supernatants. 
To establish whether NKSF acts directly on NK cells, highly 
purified NK cells were obtained by cell sorting. After stimu- 
lation with rNKSF, sorted CD56 +  CD5-  NK cells demon- 
strated substantial lysis of the NK-resistant cell line COLO 
(Fig.  1 A). These results demonstrate that  NKSF can aug- 
ment NK cytotoxicity by directly stimulating NK cells, and 
that  indirect  effects of NKSF on T  lymphocytes or other 
PBMC are not required. Furthermore, unlike NKSF-induced 
secretion of IFN-3' (18),  the enhancement  of NK cytotox- 
icity by NKSF does not seem to require the presence of nonad- 
herent,  MHC class  II-positive accessory ceils.  In  as much 
as resting CD56 di~ and CD56bng ht NK cells differ somewhat 
in  their cytolytic activities (30,  31),  we also isolated these 
two subsets of NK cells and stimulated each with rNKSF. 
NKSF augmented the MHC-unrestricted cytotoxicity of both 
CD56  aim and CD56b~ig  ht NK cells comparably (Fig.  1, B and 
C).  Finally,  sorting  experiments  confirmed  that  purified 
CD5 +CD56-  T  lymphocytes did not exhibit  "anomalous 
killing" after short-term culture with NKSF (data not shown). 
In addition to MHC-unrestricted natural killing (NK ac- 
tivity), NK cells can lyse antibody-coated target cells by ADCC 
(1, 2). Furthermore,  II.-2-activated  NK cells can lyse targets 
that  are relatively resistant  to killing by unstimulated  NK 
cells (1, 2). It is not clear whether such LAK activity represents 
a distinct cytolytic pathway or merely reflects augmented nat- 
ural killing. The effects of NKSF on all of these types of NK 
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Figure 1.  Effect of NKSF on 
cytolytic  activity  of  highly purified 
NK cells. Sorted CD56+CD5  - 
NK cells (A), CD56  dim NK cells 
(B), and CD56b~is  ht NK cells (C') 
were incubated for  18 h  with 
medium alone (open symbols) or 
NKSF 4 U/ml (filled  symbols)  and 
then tested  for cytotoxicity  against 
COLO (,4) or K562 (B and C) 
at the E/T ratios indicated. Sym- 
bols represent means of triplicate 
wells. Experiment using total NK 
cells was  repeated twice with 
similar results. 
cytotoxicity were examined,  and compared with the effects 
of other cytokines known to activate NK cells.  NKSF con- 
sistently augmented the lysis of NK-sensitive, NKoresistant, 
and antibody-coated targets (Fig. 2). NKSF enhanced K562 
killing in a manner comparable with IL-2 (Fig. 2 A), although 
optimal concentrations of NKSF appeared to be slightly in- 
ferior to optimal concentrations of IL-2 in the induction of 
LAK activity (Fig.  2 B).  Both  NKSF and IL-2 stimulated 
MHC-unrestricted killing of K562 and COLO more effec- 
tively than  did IFN-ol and IFN-y.  However, IL-2,  NKSF, 
and IFN-oe all  augmented ADCC  similarly  (Fig.  2 C). 
Upregulation of NK  Cell Adhesion Molecules (CAM)  by 
NKSE  We have previously shown that II~2 upregulates sev- 
eral NK cell adhesion molecules, and that increased levels of 
CAM may mediate enhanced lysis of NK-resistant targets by 
IL-2-activated NK cells (28). We therefore studied the effects 
of NKSF on the expression of CAM by NK cells.  NKSF- 
activated NK cells demonstrated marked upregulation of several 
adhesion  molecules,  including  CD2,  CDlla,  CD54,  and 
CD56 (Fig. 3). Indeed, the increased levels of adhesion mol- 
ecules induced by NKSF were very similar to those induced 
by IL-2. As shown previously for IL-2 (28), levels of CDllb 
were not upregulated by NKSF (data not  shown);  the in- 
creases in CAM were therefore specific and did not merely 
reflect an increased size of activated NK cells.  Unlike IL-2 
and NKSF, IFN-ot induced little change in CAM expression 
by NK cells (data not shown);  IFN-ot also stimulated NK 
cytolytic activity to a much lesser degree than  did IL-2 or 
NKSF. 
Role of  lL,2 in the Stimulation Of  NK Cells by NKSE  Since 
781  Robertson  et al. Figure 2.  Augmentation  of NK cell cytolytic activities by stimulatory 
cytokines. Enriched NK cells were incubated for 18 h with medium alone, 
230 U/ml Ib2, 4 U/ml NKSF, 1,000 U/ml IFN-~, or 1,000 U/m11FN-',/ 
as indicated and tested for cytotoxicity against K562 (A), COLO (B), or 
antibody-coated P815 (C). Means of triplicate wells from a single repre- 
sentative experiment  for each target  cell line are shown. Results  were 
confirmed in at least four experiments. The E/T ratio was 5:1 for K562 
and P815  + Ab, and 20:1 for COLO. Background killing of P815 in the 
absence of antibody (2% for medium alone, 17% for IL-2, 6% for NKSF, 
2% for IFN-c~, and 0% for INF-3~)  has been subtracted. 
the effects of NKSF and I1-2 were quite similar in several 
respects, we wished to determine whether Ib2 was involved 
in NKSF-induced activation of NK cells. A combination of 
mAbs to both I1.2K p55 and p75 abolished the augmenta- 
tion of NK killing induced by II.,2, as expected (Fig. 4 B). 
In contrast, these mAbs did not significantly inhibit the acti- 
vation of NK cells by NKSF (Fig. 4 A). Furthermore, simul- 
taneous incubation of NK  cells with both  I1.4  and  I1.2 
markedly abrogated the enhancement of NK cytotoxicity in- 
duced by Ib2 alone,  whereas the presence  of I1.4  did not 
affect NK cell activation by NKSF (data  not shown). I1.4 
also selectively inhibited the upregulation of NK cell CAM 
by II-2, but not by NKSF (data not shown). Thus, NKSF 
appears to stimulate NK cells through a distinct pathway that 
is independent of I1-2. 
Effects of NKSF on Proliferation of Resting NK Cells.  The 
observation that B lymphoblastoid  cell lines supported human 
NK ceU growth provided a rationale for the initial isolation 
and purification of NKSF (16). The effects of NKSF on NK 
cell proliferation were therefore examined. Highly purified 
NK cells demonstrated little proliferation to concentrations 
of NKSF as high as 250 U/m1 (data not shown). Compared 
with I1-2 alone,  NKSF alone induced much less NK cell 
proliferation (Table 1). This disparity did not appear to be 
due to differences in the kinetics of proliferation induced by 
NKSF and I1-2, since NK cells stimulated with NKSF for 
up to 12 d did not exhibit significantly  greater proliferation 
(data not shown). Furthermore, NKSF strongly inhibited the 
proliferation of NK ceUs  induced by I1-2 (Table 1). Such in- 
hibition was consistently seen in every experiment performed. 
The proliferative  responses of CD56  dim and CD56btig  ht NK 
calls to I1-2 are quite different:  CD56  bright NK cells consis- 
tently exhibit much greater proliferation than do CD56  d~m 
NK cells stimulated with Ib2 (25, 30, 31). It was therefore 
possible  that NKSF also affected I1.2-induced proliferation 
of  these  two  subsets  differently.  When  CD56  dim  and 
CD56  brisht NK cells were isolated  by flow cytometry and 
tested independently, however, we found that NKSF inhibited 
the proliferation of each subset by ,v80-90% (Table 1). This 
effect was not due to nonspecific inhibitory factors, because: 
(a) neutralizing heteroantiserum to NKSF largely reversed 
the inhibition; (b) highly purified CHO-derived rNKSF also 
inhibited  proliferation;  and  (c)  supernatant  from  mock- 
transfected  Cos cells did not significantly inhibit prolifera- 
tion (data  not shown). 
NKSF is a potent stimulus for IFN-7 secretion by both 
T cells and NK cells, and is synergistic with IL-2 in inducing 
IFN-3~ (16-18).  Like IFN-cx and IFN-fl,  IFN-3'  has been 
reported to have antiproliferative effects in some experimental 
systems (32). Thus, the inhibition of I1.2qnduced NK cell 
proliferation by NKSF could be mediated in part by auto- 
crine secretion of IFN-%  Although NKSF inhibited I1.2- 
induced proliferation of CD56  d~m NK cells by 89  _+  7% 
(mean +_ SD of seven experiments), 1,000 U/m1 of rlFN-y 
failed to significantly inhibit NK call proliferation (2  _+ 8% 
inhibition in five experiments). Furthermore, highly purified 
NK cells have been reported to produce IFN-'y very poorly 
due to the absence of requisite accessory cells (18). There- 
fore, it is unlikely that IFN-~/plays a major role in NKSF- 
induced inhibition of NK cell proliferation. 
Some investigators have suggested that induction of I1- 
2K p55 expression by activated NK cells is required for I1-2- 
induced proliferation (33-35).  We evaluated the possibility 
that NKSF inhibited such proliferation by decreasing NK cell 
expression  of I1-2K.  As previously described for NK cells 
stimulated with I1-2 alone (33, 34), NK cells stimulated with 
either NKSF alone or NKSF together with I1-2 express in- 
creased levels of I1-2K p55 (Fig. 5). Furthermore, NKSF ap- 
pears to upregulate the expression of I1-2R p75 by NK cells 
782  Response of Human NK Cells to NK Cell Stimulatory  Factor FRESH  IL-2  NKSF 
E 
i 
CM 
a 
o 
0 
I,,-  m 
L 
i 
m  . 
a 
0 
0 
i1 
| 
0 
11  IO 
￿9  i  (49%) 
￿9 i  i "~-2  i 
II  :: 
t  ......  ;Jo  '  iLn  ......  i 
20  ' 
(100%,)  i 
P 
lie  itii 
.j 
.t  i 
Iz  ........  i~o  .......  lin  ......  ; 
CO  56  - PE 
4S 
(9=%) 
L 
......  I~  0  ........  ~eO  ....... 
!  ("" 
-~ J  t 
bL  ........  Izll  tzOe  I 
6 
(o~,%*) 
I1  ........  I,￿9  ........  Izn  ........ 
CD  56-  PE 
i: 
40 
(ee%) 
e' 
L  .......  I|I  ........  hII ........ 
77 
(loo%*) 
CD  56  - pE 
Figure 3.  Upregulation of NK cell adhesion mole- 
cules by Ib2 and NKSF. Enriched NK cells  were stained 
with CD56-PE  and FITC-conjugated  mAb recog- 
nizing CD2, CDI1a, or CD54 immediately after iso- 
lation (FRESH) and after 6 d of culture with 1,000 
U/ml Ib2 or 4 U/ml NKSF as indicated. Two color 
immunofluoreseence analysis was performed as previ- 
ously described (28). Logarithm  of red fluorescence 
is displayed on the x-axis  and logarithm of green 
fluorescence on the y-axis. Quadrant settings, distin- 
guishing positive from background fluorescence,  were 
determined by staining  with isotype-matched control 
mAb (not shown). Numbers in the upper right corner 
of each histogram are the mean fluorescence intensity 
of FITC staining for the relevant CAM, determined 
as previously described (28); numbers in parentheses 
are the percentage of CD56 § cells that coexpresses 
the indicated CAM. Results are from one representa- 
tive experiment  out of three performed. 
80  >. 
u 
o  60 
r 
40 
r 
o.  20 
U) 
,< 
0 
A  NKSF  Stimulation 
i  i  ! 
2.5:1  5:1  10:1 
E  : T  Ratio 
80- 
60 
40 
20 
0 
B  IL  -  2  Stimulation 
Y 
2.5:1  5:1  10:1 
E  : T  Ratio 
Figure 4.  Effects of anti-Ib2R mAb 
on augmentation of NK cytotoxicity by 
cytokines. Enriched NK cells were in- 
cubated for 18 h with 2 U/ml NKSF 
(.4, squares) or 230 U/ml IL-2 (B, tri- 
angles) in the presence (filled symbols) or 
absence (open symbols) of saturating 
amounts of mAb to both the p55 and 
p75 subunits of the ID2R. Cytotoxicity 
against K562 was tested at the indicated 
E/T ratios. Symbols represent means of 
triplicate wells. Lysis of K562 by NK 
cells incubated for 18 h in medium alone 
is also shown (open circles). Data are from 
one representative experiment  out of 
three performed. 
Table  1.  Effects  of NKSF  on Proliferation  of Resting  NK  Cells 
Proliferation ([3H]TdP, incorporation) 
Culture  Total  CD56  aim  CD56  baght 
conditions*  NK cells  NK cells  NK cells 
Medium alone  291  _+  30t  298  _+  46  297  _+  44 
2  U/ml NKSF  1,906  _+  524  674  _+  103  2,043  _+  1,050 
230 U/ml IL-2  27,180  _+  7,864  11,783  _+  1,811  45,827  _+  17,017 
IL-2+NKSF  3,862  _+  1,499  1,824  _+  958  8,795  _+  6,202 
* Sorted total NK cells, CD56  dim NK cells, and CD56brig  ht NK cells were cultured with medium alone or with cytokines as indicated. Proliferation 
assays were performed  as described in Materials and Methods. 
* Mean  _+ SD of triplicate  cpm from two (total  NK cells) or four (NK cell subsets) representative  experiments. 
783  Robertson et al. Figure 5.  Expression of I1:2R subunits by NK cells activated with cytokines. Enriched NK cells were stained with CD56-PE and FITC-conjugated 
anti-I1:2R p75 (top) or anti-IL-2R  p55 (bottom) immediately  after isolation  (FRESH) or after 4 d of culture with 230 U/ml II:2, 4 U/ml NKSF, or 
both cytokines. Numbers in the upper  right corner of each histogram  represent  the percentage  of CD56 + cells that coexpresses the indicated  I1:2R 
subunit.  Results  are from one representative  experiment  out of three performed. 
(Fig.  5). Thus, NKSF does not seem to inhibit IL-2-induced 
NK cell proliferation by interfering with IL-2K expression. 
Enhanced NKSF-induced Proliferation of  NK Cells Preactivated 
In  Vitro by 11_,2.  NKSF does not induce the proliferation 
of resting PBL, but can support the proliferation of T  cells 
preactivated with mitogens or phorbol esters (16, 21). There- 
fore, we examined the effect of NKSF on the proliferation 
of NK cells preactivated in vitro. Preincubation with PMA 
or ionomycin for 18 h failed to enhance consistently NKSF- 
induced NK cell proliferation (data not shown). In contrast, 
NKSF induced about ninefold greater proliferation (fold in- 
crease in cpm, 8.8  _+  5.5; mean  _+ SD of four experiments) 
of CD56  a~m NK cells preincubated with IL-2 for 18 h com- 
pared with CD56 aim NK cells preincubated with medium 
alone for 18 h. Nevertheless, NKSF-induced proliferation of 
such preactivated NK  ceils  was  still  quite  inferior  to  the 
proliferation induced by IL-2 alone (Fig.  6 A). Similar to its 
effects on  freshly isolated  NK  cells,  NKSF  inhibited  by 
,x,80-90% the proliferation of preactivated NK cells cultured 
in IL-2 (Fig. 6 A). However, NKSF did not inhibit the prolifer- 
ation of PHA-activated T  cells to II_,2 (Fig.  6 B).  Further- 
more, as previously reported (16,  17), we found that NKSF 
could augment the proliferation of PHA-activated T cells in 
the absence of exogenous IL-2 (Fig.  6 B).  Our results thus 
suggest that NKSF specifically and selectively interferes with 
the ability of I1.-2 to  signal proliferation in NK cells. 
Effects of NKSF on NK Cells Preactivated In  Vivo by 11.,2. 
In attempts to induce prolonged activation of NK cells in 
vivo, we have administered human rlL-2 by continuous in- 
travenous infusion for 90 d to patients with advanced cancer 
(36). Progressive and selective expansion of peripheral blood 
NK  cell numbers  have  been consistently seen in  patients 
receiving IL-2 at doses of 6.0  x  10  s U/mZ/d. We examined 
the in vitro effects of NKSF  on these in vivo preactivated 
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Figure 6.  Effects of NKSF on pro- 
liferation  of lymphocytes  preactivated 
in  vitro.  Sorted  CD56  dim  NK  cells 
preactivated with 1,000 U/ml Ib2 (A) 
or sorted CD5+CD56 -  T cells preac- 
tivated with 5/~g/ml PHA (B) for 18 h 
were washed twice and then incubated 
in  medium  alone,  230  U/ml I1:2,  2 
U/ml NKSF, or both cytokines for 4 d. 
Mean  cpm of triplicate  wells  from a 
single experiment  are shown.  Experi- 
ment assessing  NK cell proliferation was 
repeated three times with similar results. 
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isolated from these patients can mediate modest lysis of the 
NK-resistant cell line COLO, and this killing is markedly 
enhanced by brief exposure to exogenous I1.-2 in vitro (Fig. 
7). Furthermore, overnight incubation with 4 U/ml of NKSF 
augmented the cytolytic activity of in vivo expanded NK cells 
as effectively as incubation with 230 U/ml of Ib2 (Fig. 7). 
We also examined the effects of NKSF on the proliferation 
of NK cells preactivated in vivo with I1:2. NKSF by itself 
induced a modest proliferation of sorted NK cells from these 
patients, but NKSF inhibited I1:2-induced NK cell prolifer- 
ation (data not shown). These results are very similar to those 
seen with NK cells from normal donors preactivated in vitro 
with Ib2. Thus, NK cells expanded in vivo by chronic ad- 
ministration of Ib2 remain fully responsive  to NKSF. 
Discussion 
NKSF is a novel heterodimeric cytokine that was origi- 
nally isolated from the medium of EBV-transformed human 
B lymphoblastoid cell lines (16). Although NKSF has been 
previously reported to augment the MHC-unrestricted cyto- 
lyric activity of normal PBL (16, 19), the direct effects of 
NKSF on human NK cells have not been described in detail. 
Our results conclusively demonstrate that resting NK cells 
can respond to NKSF in the absence of any other stimuli. 
The presence of accessory cells, reportedly obligate for NKSF- 
induced IFN-'y secretion (18), does not appear to be required 
for augmentation of NK cytotoxicity. Both the CD56 aim 
and the CD56  b~ght NK cell subsets demonstrate enhanced 
cytolytic activity after stimulation with NKSF. Furthermore, 
NKSF augments all known NK cytolytic activities, including 
lysis of NK-sensitive targets (NK activity), lysis of NK-resistant 
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Cytolytic activity of NK cells expanded in vivo by II.,2. PBMC 
("~75%  CD56+CD3 -) from a patient who had received rlb2 6  x  l0  s 
U/m2/d by continuous intravenous infusion for 12 wk were isolated and 
cryopreserved. These cells were subsequently  thawed,  incubated  for 18 h 
with medium alone (open triangles), 230 U/ml IL-2 (filled circles), or 4 U/ml 
NKSF (open circles) and tested for cytotoxicity against COLO. Experiment 
was repeated once with PBMC from a different patient with identical results. 
targets (LAK activity), and lysis of antibody-coated targets 
(ADCC). NKSF appears to be more efficient than either II:2 
or the IFNs in augmenting NK cytotoxicity; marked enhance- 
ment of NK lyric activity requires nanomolar concentrations 
of I1:2 or IFN but only picomolar concentrations of NKSF 
(16). However,  optimal concentrations of I1:2 ("~5-10 nM) 
consistently induce greater cytolytic activity against  NKo 
resistant targets than do optimal concentrations (m1-10 pM) 
of NKSF (Fig. 2 and reference 16). Like II~2-activated NK 
cells (28),  NKSF-activated  NK cells demonstrate increased 
expression  of several CAM,  including CD2,  CDlla,  and 
CD54.  In as much as these structures have been shown to 
participate in NK cell adhesion to and lysis of target cells 
(28, 37, 38), NKSF could in part augment NK cytolytic ac- 
tivity by upregulating these or other adhesion molecules. 
NKSF and I1:2 appear to activate human NK cells through 
distinct pathways that interact in complex ways. The effects 
of NKSF on NK cells do not require direct participation of 
I1:2, since anti-I1:2R mAbs that completely abrogate 11:2- 
induced NK cytotoxicity have little effect on NKSF-induced 
killing. Furthermore, I1:4 coincubation selectively inhibited 
the augmented cytolytic activity induced by IL-2 but not by 
NKSF. Nonetheless, I1:2 pretreatment rendered NK cells more 
responsive to the weak proliferative signal induced by NKSF. 
Increased I1:12 binding sites have apparently been detected 
on a subset of human PBMC stimulated with IL-2 (21), and 
hence, upregulation of NKSF receptors could mediate the 
increased NKSF-induced proliferation of IL-2-activated NK 
cells. Conversely, we found that NKSF potently inhibits NK 
cell proliferation in response to I1:2, despite stimulating in- 
creased NK cell expression of both IL-2R p55 and p75. Fur- 
ther study is needed to elucidate the mechanisms underlying 
these complicated interactions between effects of NKSF and 
I1:2 on human NK cells. 
In contrast to its effects on NK cells, NKSF did not in- 
hibit the proliferation of PHA-activated T cells to I1:2. NKSF 
thus appears to interfere selectively  with the proliferative signal 
induced by I1:2  in NK cells. NKSF is composed of two 
subunits, p40 and p35, which are encoded by distinct genes 
(17, 20). The p40 chain, which has significant homology to 
the IL-6R (39), does not appear to be biologically active by 
itself; it is not clear whether the p35 chain alone has bioac- 
tivity (17). It has been suggested that NKSF may actually 
represent a soluble heterodimer comprised of a cytokine (p35) 
and part of its receptor (p40),  and that either p35 or the 
p35/p40 complex might interact with additional cell surface 
receptor subunits (39). The differential effects of NKSF on 
the proliferation of activated NK cells and activated T cells 
could reflect differences in the NKSF receptor subunits ex- 
pressed by the two cell types. Alternatively, identical receptors 
for NKSF may activate different second messenger pathways 
in T cells and NK cells upon ligand binding. Understanding 
of the disparate effects of NKSF on NK cells and T cells will 
require better characterization of the NKSF receptor and 
detailed examination of the biochemical and genetic altera- 
tions induced by NKSF. 
Treatment with I1:2, with or without adoptive transfer 
785  Robertson et al. of activated autologous lymphocytes, has produced tumor 
regressions  in some patients with advanced renal cell carci- 
noma  and  melanoma  (13, 14). However,  successful  im- 
munotherapy using II.-2 has generally required administra- 
tion of high doses of the cytokine and has been associated 
with substantial toxicity (13-15). Several groups have under- 
taken modifications of the original high-dose IL-2 regimen, 
in attempts to enhance antitumor activity and to limit tox- 
icity (36, 40-42). We have administered prolonged continuous 
intravenous infusions of IL-2 to patients with advanced cancer 
(36).  Ib2 was well tolerated in doses as high as 6.0  x  10  s 
U/m2/d  for  90  consecutive days.  Such  therapy produced 
marked expansion of  peripheral blood NK cells, and the PBL 
of these patients demonstrated enhanced killing of  NK-sensitive 
and NK-resistant targets. The cytolytic activity of these in 
vivo preactivated NK cells can be further augmented by brief 
in vitro incubation with high concentrations of I1-2 (36). 
In the present study, we found that picomolar concentra- 
tions of NKSF were as effective as nanomolar concentrations 
of I1,2 in augmenting the cytolytic activity of NK cells ex- 
panded in vivo. Furthermore, the effects of NKSF on prolifer- 
ation of these NK cells were very similar to the effects of 
NKSF on normal NK cells preactivated in vitro with Ib2. 
Thus, NK cells expanded in vivo by chronic exposure to low 
concentrations of I1,2  seem  to remain fully responsive  to 
NKSF. It is conceivable  that II.-2 and NKSF could be used 
together for anticancer immunotherapy. Since NKSF by it- 
self  induces very little NK cell proliferation,  a rational strategy 
might include low-dose continuous infusions of Ib2 to ex- 
pand NK cells in vivo, followed by administration of NKSF 
to augment NK cell cytolytic activity. NKSF administered 
in low doses might prove less toxic than high doses of Ib2, 
while producing similar activation of NK cytotoxicity. Fur- 
ther evaluation of NKSF as a potential therapeutic cytokine 
appears  warranted. 
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